| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | IDE397 MTAP‑deletion cancers — conference presentation | Phase 1/2 | — | Small Molecules | Oncology | ||
Phase 1/2 data readout example | IDE397 MTAP‑deletion cancers — conference presentation | Phase 1/2 | — | Small Molecules | Oncology | ||
Phase 1/2 data readout example | IDE397 MTAP‑deletion cancers — conference presentation | Phase 1/2 | — | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
IDEAYA Biosciences, Inc.$36.28
+1.37 (+3.92%)
C 52Pipeline Score Overvalued Pharma · Commercial
Market Cap
2.56 B
EPS
-1.58
P/E Ratio
-
Value Trade
30.21 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.56 M
R&D Expenses
95.73 M
Operating CF
-75.17 M
Total Assets
1.03 B
Total Liabilities
93.08 M
Equity
937.27 M
D/E Ratio
12,345
1.78 %
Week
-8.58 %
1 Month
-11.55 %
3 Month
-12.4 %
6 Month
43 %
5 Year
107.86 %
All Time
Cash Data
Cash Position
671.20 M
Monthly Burn
25.06 M
Runway
25.4 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
2.26 M
52 Week Range
18.77 - 39.28
% held by Insiders
5.45 %
% held by Institutions
96.31 %
Enterprise Value
1.91 B
Total Shares
87.87 M
Short %
13.02 %
Float Shares
87.08 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C52
Pipeline Score $768M
Pipeline ValueOvervalued
Valuation Signal8
Drugs Scored0.3x
rNPV / MCap Top 81%
Small Cap (rank 173 of 905)
Percentile RankIDEAYA Biosciences, Inc. carries a moderate pipeline score (52/100), with $1.2B risk-adjusted pipeline value, led by IDE-161 in Advanced or Metastatic Solid Tumors (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDE-161 Small molecule | Advanced or Metastatic Solid Tumors | Phase 1 | NCT05787587 | 5% | $941M | ACTIVE NOT_RECRUITING | 216 | FAST | C (45) | May 1, 2027 | MODERATE_RISK | MEDIUM Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
darovasertib | metastatic uveal melanoma | Phase 2/3 | 2025-08-05 | |||
darovasertib | metastatic uveal melanoma | Phase 2/3 | 2025-08-05 | |||
darovasertib | metastatic uveal melanoma | Phase 2/3 | 2025-08-05 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IDYA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IDEAYA Biosciences, Inc. (IDYA) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
IDYA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IDYA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IDYA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IDYA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
IDYA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IDYAIDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
IDEAYA Biosciences has elected Yujiro S. Hata as Chairman of the Board. Hata, who is also the President and CEO, has been instrumental in the company's evolution into a leading precision medicine oncology firm. The company is focused on developing breakthrough therapies for cancer, addressing significant unmet medical needs.
Read more →IDYAIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE892, a promising PRMT5 inhibitor, in combination with IDE397 for treating MTAP-deleted pancreatic and lung cancers. The trial aims to address the significant unmet need for effective therapies in these cancer types, where MTAP deletion is prevalent. Preclinical results indicate strong anti-tumor activity, supporting the rationale for this combination therapy.
Read more →IDYAIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
IDEAYA Biosciences has successfully closed its public offering of 7,222,225 shares at $27.00 each, raising approximately $345 million. The offering included a full exercise of the underwriters' option for an additional 1,666,669 shares. The company aims to advance its precision medicine oncology initiatives with these funds.
Read more →IDYAIDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
IDEAYA Biosciences has announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $300 million. The offering includes 5,555,556 shares of common stock priced at $27.00 each and pre-funded warrants at $26.9999. The transaction is expected to close around June 10, 2026, subject to customary conditions.
Read more →IDYAIDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
IDEAYA Biosciences announced a proposed public offering of up to $300 million in common stock and pre-funded warrants. The offering is subject to market conditions, and underwriters have a 30-day option to purchase an additional $45 million. The company aims to leverage this capital for its precision oncology initiatives.
Read more →IDYAIDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
IDEAYA Biosciences has announced a clinical collaboration with Roche to evaluate the efficacy of IDE892, a PRMT5 inhibitor, in combination with Roche's RG6505 for treating MTAP-deleted RAS-mutant pancreatic cancer. The trial aims to address the high unmet need in this patient population. Both companies will retain commercial rights to their respective compounds.
Read more →IDYAIDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
IDEAYA Biosciences and Servier presented complete data from the Phase 2/3 OptimUM-02 trial at ASCO 2026, showcasing the darovasertib combination's effectiveness in treating HLA*A2:01 negative metastatic uveal melanoma. The trial demonstrated significant improvements in response rates and progression-free survival compared to existing therapies. The FDA is reviewing the NDA for this combination under the Real-time Oncology Review program, which may expedite approval.
Read more →IDYAHLA, human leukocyte antigen. mOS, median overall survival. mPFS, median progression free survival. PKC, protein kinase C. 1. Khoja L, et al. J Clin Oncol. 2025;43(suppl) [abstract 9539]. 2. Rantala ES, et al. Melanoma R
The OptimUM-02 trial evaluated the first-line treatment of darovasertib plus crizotinib for patients with HLA-A*02:01 negative metastatic uveal melanoma. Results indicated a significant improvement in progression-free survival (PFS) compared to standard treatments, demonstrating a 58% reduction in the risk of disease progression or death. The combination therapy presents a potential new option for a patient population with historically limited treatment choices, given the absence of FDA-approved therapies for this subgroup.
Read more →IDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635 c 4
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635 c 4
Read more →IDYAIDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
IDEAYA Biosciences announced its participation in the 2026 Jefferies Global Healthcare Conference. The company will host a fireside chat and an AI panel discussion featuring its CEO, Yujiro S. Hata. Live webcasts of the events will be available, along with a replay for 30 days post-event. IDEAYA focuses on precision medicine for oncology.
Read more →IDYAIDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences reported positive topline results from its OptimUM-02 trial, paving the way for its first NDA submission for accelerated approval. The company anticipates a catalyst-rich second half of 2026 with updates on several clinical programs. However, it also reported a net loss increase and a decrease in cash reserves compared to the previous quarter.
Read more →IDYAIDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
IDEAYA Biosciences announced that the FDA will review its NDA for darovasertib in combination with crizotinib for patients with HLA*A2-negative metastatic uveal melanoma. The decision follows positive topline results from the OptimUM-02 trial, which showed a 58% reduction in disease progression risk. IDEAYA plans to initiate the RTOR submission process in May 2026.
Read more →IDYAIDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences announced a late-breaking abstract oral presentation at ASCO 2026, focusing on the OptimUM-02 trial of darovasertib combined with crizotinib for HLA*A2-negative metastatic uveal melanoma. The presentation will reveal complete data not previously disclosed. Dr. Marlana Orloff will present the findings on June 1, 2026.
Read more →IDYAIDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences and Servier announced positive topline results from their Phase 2/3 trial, OptimUM-02, for darovasertib combined with crizotinib in treating first-line HLA-A*02:01-negative metastatic uveal melanoma. The combination showed a statistically significant improvement in median progression-free survival compared to the investigator choice of therapy. The study provides promising data for a new treatment option in a patient population with high unmet medical need.
Read more →IDYAIDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
IDEAYA Biosciences plans to announce topline results from its Phase 2/3 OptimUM-02 trial on April 13, 2026. The trial evaluates darovasertib combined with crizotinib for treating first-line HLA*A2-negative metastatic uveal melanoma. A conference call and webcast will provide insights from IDEAYA's management and a key opinion leader.
Read more →IDYAIDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE574, a Potential First In Class Dual Inhibitor of KAT6 7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE574, a Potential First In Class Dual Inhibitor of KAT6 7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Read more →IDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
IDEAYA Biosciences has announced the enrollment of the first patient in a Phase 1 clinical trial evaluating the combination of IDE849 and IDE161 for DLL3 upregulated solid tumors. The trial aims to assess the safety and efficacy of this first-in-class combination in treating conditions such as small cell lung cancer and melanoma. Preliminary data indicates promising results, with multiple partial responses observed in patients.
Read more →IDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced the granting of non-qualified stock options to two new employees as part of its 2023 Employment Inducement Incentive Award Plan. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to the company. The stock options have a 10-year term and will vest over four years, contingent on continued employment.
Read more →IDYAIDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
IDEAYA Biosciences announced its participation in investor relations events and provided updated guidance on the topline results from the Phase 2/3 OptimUM-02 trial for darovasertib. The events will take place on May 12 and May 19, 2026, with webcasts available for investors. The company emphasizes its commitment to precision oncology and the development of targeted therapies.
Read more →IDYAIDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
Read more →IDYAIDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
Read more →IDYABiocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Biocytogen Pharmaceuticals announced the first patient dosing in IDEAYA's Phase 1 trial of IDE034, a bispecific ADC targeting B7H3/PTK7. This milestone triggers a $5 million payment to Biocytogen. The trial aims to evaluate IDE034's safety and tolerability, with potential combination therapies planned. IDE034 is designed to selectively target tumor cells, indicating promising therapeutic potential.
Read more →IDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
IDEAYA Biosciences has announced the enrollment of the first patient in its Phase 1 trial for IDE034, a bispecific TOP1 antibody-drug conjugate targeting B7H3 and PTK7. The trial will assess the safety and tolerability of IDE034 as a monotherapy and in combination with IDE161, a proprietary PARG inhibitor. This milestone triggers a $5 million payment to Biocytogen, highlighting the significance of IDE034 in IDEAYA's oncology portfolio.
Read more →IDYAIDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
IDEAYA Biosciences has appointed Dr. Theodora Ross as Chief Development Officer, a newly created role. Dr. Ross will lead early clinical development for the company's oncology pipeline. She brings over 30 years of experience, previously serving at AbbVie. The leadership is optimistic about her impact on the company's growth and clinical strategies.
Read more →IDYAIDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
IDEAYA Biosciences reported a strong fourth quarter and full year 2025, highlighting successful clinical execution and pipeline expansion. The company completed enrollment in its key clinical trial, OptimUM-02, and submitted IND filings for two promising drug candidates. Financially, IDEAYA ended the year with approximately $1.05 billion in cash, despite a net loss of $113.7 million.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
IDEAYA Biosciences announced its participation in two upcoming investor relations events in February 2026. The events include Citi's Virtual Oncology Leadership Summit and a Virtual Fireside Chat hosted by Evercore ISI. Live audio webcasts will be available, with replays accessible for 30 days post-event. IDEAYA aims to advance precision oncology therapies.
Read more →IDYACertain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the "
IDEAYA Biosciences, Inc. provided forward-looking statements regarding its future financial performance and clinical programs during a recent healthcare conference. These statements highlight the company's ambitions in developing precision medicines, specifically in oncology. However, they also acknowledge the inherent risks associated with drug development and the uncertainties surrounding clinical trials, regulatory approvals, and market dynamics. Investors are advised that success relies on multiple assumptions that may evolve over time.
Read more →IDYAIDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J P Morgan Healthcare Conference
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J P Morgan Healthcare Conference
Read more →IDYAIDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences announced its participation in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12, 2026. The event will feature a live audio webcast of the presentation and Q&A session, which will be accessible for 30 days after the event. IDEAYA focuses on precision medicine and aims to develop targeted therapies for cancer.
Read more →IDYAIDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences has completed enrollment of 435 patients in its Phase 2/3 trial (OptimUM-02) for darovasertib combined with crizotinib in treating HLA*A2-negative metastatic uveal melanoma. The company anticipates reporting median progression-free survival data in Q1 2026, which may support an accelerated approval filing. The trial aims to address the significant unmet need in this aggressive cancer type.
Read more →IDYAIDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
IDEAYA Biosciences has submitted an IND application for IDE574, a dual inhibitor targeting KAT6 and KAT7, with plans to initiate a Phase 1 trial in early 2026. The drug aims to disrupt tumor lineage identity and has shown promising anti-tumor activity in preclinical models. The company plans to present further data at a medical conference in 2026.
Read more →IDYAIDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
IDEAYA Biosciences has received IND clearance from the FDA for IDE034, a bispecific ADC targeting solid tumors expressing B7H3 and PTK7. The Phase 1 trial is set to begin in Q1 2026, focusing on various cancers. Preclinical studies show promising anti-tumor activity, supporting its potential as a first-in-class therapy.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
IDEAYA Biosciences will participate in two investor relations events in December 2025. The company is set to present at Citi's 2025 Global Healthcare Conference on December 2 and the 8th Annual Evercore Healthcare Conference on December 3. A live audio webcast will be available for both events, with replays accessible for 30 days.
Read more →IDYAIDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences reported strong financial results for Q3 2025, highlighting a net income of $119.2 million and a significant increase in collaboration revenue due to a partnership with Servier. The company continues to advance its pipeline, including multiple clinical data updates presented at major medical conferences. IDEAYA's cash reserves have also grown, supporting its ongoing operations and development efforts.
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Balance Sheet Data ( in thousands ) September 30
IDEAYA Biosciences has released their third quarter financial results for 2025, highlighting significant progress in several clinical trials and partnership developments. Notably, they reported promising data from their darovasertib trials for metastatic uveal melanoma, with plans for accelerated approval in the U.S. Additionally, they secured a licensing agreement with Servier that extends their capabilities into 2030. The company also maintains a strong cash position to support ongoing operations and development.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
IDEAYA Biosciences presented positive Phase 2 data for darovasertib in the neoadjuvant treatment of primary uveal melanoma at ESMO 2025. The trial showed significant tumor shrinkage and reduced risk of vision loss. This therapy addresses a critical unmet need, as there are currently no approved systemic treatments for this condition. The company is also advancing a Phase 3 trial and aims for accelerated approval in the U.S.
Read more →IDYAIDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences has announced positive median overall survival results from its Phase 1/2 trial of darovasertib combined with crizotinib for first-line treatment of metastatic uveal melanoma. The trial showed a median overall survival of 21.1 months and a disease control rate of 90%. The data will be presented at the 2025 Society for Melanoma Research Congress in Amsterdam. The company is also advancing a registration-enabling Phase 2/3 trial, OptimUM-02, targeting accelerated approval.
Read more →IDYAIDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
IDEAYA Biosciences announced positive initial data from its Phase 1/2 trial of IDE397 combined with Trodelvy for treating MTAP-deletion urothelial cancer. The trial included 19 patients, with a notable 68% having progressed after multiple therapies. The results indicate a promising early response rate, paving the way for further testing in non-small cell lung cancer.
Read more →IDYAIDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
Read more →IDYAIDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
IDEAYA Biosciences and Hengrui Pharma presented positive Phase 1 data for IDE849, a DLL3-targeting ADC, at the IASLC 2025 World Conference on Lung Cancer. The trial involved 100 patients, showing an overall response rate of 73.2% in evaluable small cell lung cancer patients. The companies plan to advance IDE849's development for various cancers, addressing significant unmet medical needs.
Read more →IDYAIDEAYA Biosciences Announces First Patient In for Phase 1 2 Combination Trial of IDE397, A Potential First in Class MAT2A Inhibitor, and Trodelvy R in MTAP Deletion Non Small Cell Lung Cancer
IDEAYA Biosciences Announces First Patient In for Phase 1 2 Combination Trial of IDE397, A Potential First in Class MAT2A Inhibitor, and Trodelvy R in MTAP Deletion Non Small Cell Lung Cancer
Read more →IDYAIDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deletion Solid Tumors
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deletion Solid Tumors
Read more →IDYAServier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Read more →IDYAIDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Announces Agenda for 10 Year Anniversary R D Day on September 8, 2025
IDEAYA Biosciences Announces Agenda for 10 Year Anniversary R D Day on September 8, 2025
Read more →IDYAIDEAYA Biosciences, Inc Reports Second Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports Second Quarter 2025 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Balance Sheet Data ( in thousands ) June 30
IDEAYA Biosciences, Inc. reported positive financial results for Q2 2025, with several key clinical milestones on the horizon. The company is on track to present median progression-free survival data for the darovasertib and crizotinib combination in metastatic uveal melanoma by year-end 2025, which could facilitate a U.S. accelerated approval. Additionally, clinical updates from various trials are set to be showcased at major medical conferences. IDEAYA also announced a robust financial position with around $992 million in cash, expected to fund operations until 2029.
Read more →IDYAIDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
Read more →IDYAIDEAYA Biosciences Announces 10 Year Anniversary R D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
IDEAYA Biosciences Announces 10 Year Anniversary R D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
Read more →IDYAIDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 SHR 4849 , a Potential First in Class DLL3 TOP1 ADC
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 SHR 4849 , a Potential First in Class DLL3 TOP1 ADC
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
Read more →IDYAIDEAYA Biosciences, Inc Reports First Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports First Quarter 2025 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Balance Sheet Data ( in thousands ) March 31
IDEAYA Biosciences, Inc. reported its financial results for the first quarter of 2025, highlighting a robust cash position of approximately $1.05 billion. The company is advancing its darovasertib program with over 300 patients currently enrolled in a pivotal trial, targeting to file for accelerated approval by the end of 2025. IDEAYA also made significant progress with its clinical pipeline, including new data expected from various trials throughout the year. The company has a promising future with multiple updates and IND filings planned for several innovative programs.
Read more →IDYAIDEAYA Biosciences Announces US FDA IND Clearance for IDE849, a Potential First in Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
IDEAYA Biosciences Announces US FDA IND Clearance for IDE849, a Potential First in Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
Read more →IDYAIDEAYA Biosciences Announces Phase 1 2 Expansion for IDE397 and Trodelvy R Combination in MTAP Deletion Urothelial Cancer
IDEAYA Biosciences Announces Phase 1 2 Expansion for IDE397 and Trodelvy R Combination in MTAP Deletion Urothelial Cancer
Read more →IDYAIDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
Read more →IDYAIDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 GSK959 , a Phase 1 Werner Helicase Inhibitor
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 GSK959 , a Phase 1 Werner Helicase Inhibitor
Read more →IDYAIDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI ML Enabled Drug Discovery for Unprecedented First in Class Oncology Targets
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI ML Enabled Drug Discovery for Unprecedented First in Class Oncology Targets
Read more →IDYAIDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy R and IDE397 in MTAP Deletion NSCLC
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy R and IDE397 in MTAP Deletion NSCLC
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Balance Sheet Data ( in thousands ) December 31
IDEAYA Biosciences, Inc. reported its fourth quarter and full year 2024 financial results, highlighting significant enrollment in key clinical trials including a potential registration-enabling trial for darovasertib in 1L HLA-A2-negative metastatic uveal melanoma. The company is on track to announce multiple clinical data updates throughout 2025, supported by a strong financial position with approximately $1.1 billion in cash reserves. Additionally, IDEAYA revealed plans to advance several new compounds into clinical studies, including IDE397 and IDE892, while also winding down a collaboration with Amgen.
Read more →IDYAIDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Announces Participation at the 43rd Annual J P Morgan Healthcare Conference and 2025 Corporate Guidance
IDEAYA Biosciences Announces Participation at the 43rd Annual J P Morgan Healthcare Conference and 2025 Corporate Guidance
Read more →IDYAIDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors Exclusive global license outside of Greater China for SHR-4849, a
IDEAYA Biosciences has signed an exclusive global licensing agreement with Hengrui Pharma for SHR-4849, a DLL3-targeting ADC in development for small cell lung cancer (SCLC) and neuroendocrine tumors (NET). SHR-4849 has shown promising results in Phase 1 trials, demonstrating a high response rate among treated SCLC patients. The agreement includes a potential total of $1.045 billion in payments and royalties for Hengrui Pharma. IDEAYA plans to file a U.S. IND for SHR-4849 within the next six months, aiming to address significant gaps in treatment for these solid tumors.
Read more →IDYAIDEAYA Announces IDMC Recommendation of Move Forward Dose in Part 2a of Registration Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA A2 Negative Metastatic Uveal Melanoma
IDEAYA Announces IDMC Recommendation of Move Forward Dose in Part 2a of Registration Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA A2 Negative Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces Development Candidate Nomination of IDE251, a Potential First in Class KAT6 7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First in Class KAT6 7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Read more →IDYAIDEAYA Announces Agenda for Investor R D Day Webcast on December 16, 2024
IDEAYA Announces Agenda for Investor R D Day Webcast on December 16, 2024
Read more →IDYAIDEAYA Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
IDEAYA Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
Read more →IDYAIDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best in Class MTA cooperative PRMT5 Inhibitor
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best in Class MTA cooperative PRMT5 Inhibitor
Read more →IDYAIDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Read more →IDYAIDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R D Day
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R D Day
Read more →IDYAIDEAYA Announces Development Candidate Nomination of IDE034, a Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC and Option Exercise with Biocytogen
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC and Option Exercise with Biocytogen
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update • Enrollment in darovasertib + crizotinib 1L HLA-A2+ MUM potential Ph2/3 registration-enabling trial is ahead of s
IDEAYA Biosciences reported its third quarter 2024 results, highlighting significant progress in its clinical pipeline. The company announced that enrollment for its darovasertib trial exceeded 150 patients and that positive interim results were achieved for ocular tumor shrinkage and eye preservation. Additionally, IDEAYA received IND clearance for its Werner Helicase candidate and successfully raised $302.4 million in financing. The company is on track to initiate key trials in early 2025.
Read more →IDYAIDEAYA Biosciences Announces IND Clearance for Werner Helicase Development Candidate IDE275 GSK959 for a Phase 1 Study in MSI High Solid Tumors
IDEAYA Biosciences Announces IND Clearance for Werner Helicase Development Candidate IDE275 GSK959 for a Phase 1 Study in MSI High Solid Tumors
Read more →IDYAIDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP Deletion Urothelial and Lung Cancer as Late Breaker Oral Presentation at EORTC NCI AACR 2024
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP Deletion Urothelial and Lung Cancer as Late Breaker Oral Presentation at EORTC NCI AACR 2024
Read more →IDYAIDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36 th Edition of the EORTC-NCI-AACR Symposium South San Francisco, CA
IDEAYA Biosciences has announced the late-breaking oral presentation of the Phase 1 expansion results of its first-in-class MAT2A inhibitor, IDE397, targeting MTAP-deleted lung and urothelial cancers. This presentation will take place at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain from October 23 to 25, 2024. Additionally, IDEAYA will showcase other preclinical data on its therapies through poster presentations. The event is expected to enhance awareness of IDEAYA's innovative oncology approaches.
Read more →IDYAIDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
Read more →IDYAIDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
Read more →IDYAIDEAYA Biosciences Appoints Douglas B Snyder as Senior Vice President, General Counsel
IDEAYA Biosciences Appoints Douglas B Snyder as Senior Vice President, General Counsel
Read more →IDYAIDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update • Darovasertib achieves triple-digit enrollment in Phase 2/3 trial in 1L HLA-A2*02:01(-) MUM; and 50 patients enr
IDEAYA Biosciences, Inc. reported its financial results for Q2 2024, highlighting progress in its clinical programs. The company achieved triple-digit enrollment in the Phase 2/3 trial of darovasertib for neoadjuvant uveal melanoma and reported preliminary proof-of-concept for IDE397 in MTAP-deletion cancers. With a solid cash position of $952.7 million, IDEAYA is well-funded for its pipeline advancements, including plans for an investor R&D day later this year. Upcoming milestones include a Type C meeting with the FDA and updates on multiple clinical trials in H2 2024.
Read more →IDYAintellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further descriptio
IDEAYA Biosciences has announced a collaboration with Biocytogen Pharmaceuticals for a first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate program. The agreement allows IDEAYA exclusive global rights to develop this therapeutic, which targets multiple solid tumors and has potential for combination with their existing DNA Damage Repair pipeline. The partnership aims to leverage Biocytogen's advanced technology to enhance therapeutic precision. IDEAYA expects to nominate a development candidate in the latter half of 2024.
Read more →IDYAIDEAYA Biosciences Announces Option and License Agreement for Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC Program with Biocytogen
IDEAYA Biosciences Announces Option and License Agreement for Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC Program with Biocytogen
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
Read more →IDYAIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares
Read more →IDYAIDEAYA Announces Proposed Public Offering of Common Stock and Pre Funded Warrants
IDEAYA Announces Proposed Public Offering of Common Stock and Pre Funded Warrants
Read more →IDYAIDEAYA Announces Pricing of Public Offering
IDEAYA Announces Pricing of Public Offering
Read more →IDYAIDEAYA Announces Pricing of Public Offering IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants....
IDEAYA Biosciences, Inc. has announced a public offering of common stock and pre-funded warrants, totaling 7,228,572 shares of common stock, priced at $35.00 each. This offering is expected to raise approximately $263 million before expenses, with a closing date anticipated around July 11, 2024. The investment banks J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies, and RBC Capital Markets are set to manage the offering. IDEAYA has also granted underwriters a 30-day option to purchase additional shares.
Read more →IDYAIDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First in Class MAT2A Inhibitor in MTAP Deletion Urothelial and Lung Cancer
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First in Class MAT2A Inhibitor in MTAP Deletion Urothelial and Lung Cancer
Read more →IDYAIDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
Read more →IDYAIDEAYA Biosciences Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy R Combination in MTAP Deletion Bladder Cancer
IDEAYA Biosciences Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy R Combination in MTAP Deletion Bladder Cancer
Read more →IDYAIDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First in Class Phase 2 MAT2A Inhibitor Targeting MTAP Deletion Solid Tumors
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First in Class Phase 2 MAT2A Inhibitor Targeting MTAP Deletion Solid Tumors
Read more →IDYAIDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company Sponsored Neoadjuvant Study
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company Sponsored Neoadjuvant Study
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Appoints Daniel A Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
IDEAYA Biosciences Appoints Daniel A Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
Read more →IDYAC O R R E C T I O N IDEAYA Biosciences, Inc
C O R R E C T I O N IDEAYA Biosciences, Inc
Read more →IDYAIDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma ~67% eye preservation rate (6 of 9 enucleation patients) with darovasertib monotherapy neoadjuvant uveal melanoma treatment Median tumor shrinkage...
IDEAYA Biosciences announced promising results from its Phase 2 trial of darovasertib in treating neoadjuvant uveal melanoma. In the study, 15 patients scheduled for enucleation received darovasertib, leading to a 67% eye preservation rate and a median tumor shrinkage of approximately 45% after six months. The treatment was generally well tolerated, with most adverse events being mild; however, 13% of patients experienced Grade 3 adverse events. More detailed findings will be presented at the ASCO 2024 oral presentation in June.
Read more →IDYAIDEAYA Biosciences, Inc Reports First Quarter 2024 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports First Quarter 2024 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Bal ance Sheet Data ( in thousands ) March 31
IDEAYA Biosciences, Inc. has provided a business update and announced its first-quarter financial results for 2024. The company is advancing several clinical programs, including darovasertib for uveal melanoma and IDE397 for MTAP-deletion solid tumors. IDEAYA aims to present data at ASCO 2024 regarding ongoing trials and anticipates further developments in its clinical pipeline. With a strong cash position, IDEAYA is well-positioned for continued growth and development in the oncology space.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
Read more →IDYAIDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
Read more →IDYAIDEAYA Biosciences Announces Selection of Move Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP Deletion Squamous Non Small Cell Lung Cancer
IDEAYA Biosciences Announces Selection of Move Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP Deletion Squamous Non Small Cell Lung Cancer
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
Read more →IDYAIDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
Read more →IDYAAbout IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach
IDEAYA Biosciences announced a clinical collaboration with Merck to evaluate IDE161, a PARG inhibitor, in combination with KEYTRUDA for treating endometrial cancer. This Phase 1 trial targets both microsatellite instability-high and stable forms of the cancer. IDE161 is currently undergoing a monotherapy expansion stage with prior encouraging results noted in various solid tumors. The collaboration allows IDEAYA to advance its investigational treatments while leveraging Merck's resources for the trial.
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Bal ance Sheet Data ( in thousands ) December 31
IDEAYA Biosciences, Inc. reported robust financial results for Q4 and full-year 2023, focusing on its precision medicine initiatives. The company is targeting several important clinical updates and collaborations for its lead candidates, including darovasertib and IDE397, set for mid-2024. IDEAYA has a substantial cash balance to support operations through 2028, which underscores its commitment to advancing multiple first-in-class oncology programs.
Read more →IDYAIDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Announces Participation at the 42nd Annual J P Morgan Healthcare Conference and 2024 Corporate Guidance
IDEAYA Biosciences Announces Participation at the 42nd Annual J P Morgan Healthcare Conference and 2024 Corporate Guidance
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
Read more →IDYAUnder the clinical study collaboration and supply agreement, Gilead will provide drug supply to IDEAYA, which will be the sponsor of the Phase 1 clinical combination trial. IDEAYA and Gilead each retain all commercial ri
IDEAYA Biosciences has announced a clinical study collaboration with Gilead Sciences to evaluate the efficacy and safety of a combination therapy involving IDE397 and Trodelvy for treating MTAP-deletion bladder cancer. Under the collaboration, IDEAYA will sponsor a Phase 1 clinical trial, with Gilead providing Trodelvy. This collaboration focuses on a patient population with a high unmet medical need, given the lack of approved therapies for MTAP-deletion bladder cancer. The use of a MAT2A inhibitor alongside an ADC could potentially lead to innovative treatment options for patients with solid tumors exhibiting MTAP deletions.
Read more →IDYAIDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy R and IDE397 Combination in MTAP Deletion Bladder Cancer
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy R and IDE397 Combination in MTAP Deletion Bladder Cancer
Read more →IDYAIDEAYA Announces Agenda for Investor R D Day Webcast on December 4, 2023
IDEAYA Announces Agenda for Investor R D Day Webcast on December 4, 2023
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Bal ance Sheet Data ( in thousands )
IDEAYA Biosciences, Inc. reported its third-quarter 2023 financial results, showing a strong balance sheet with $511.1 million in cash and marketable securities. The company is advancing multiple clinical trials, including a Phase 2/3 trial for darovasertib in metastatic uveal melanoma and ongoing studies for IDE397 and IDE161 targeting various solid tumors. IDEAYA has received Fast Track Designation for IDE161 and is planning further development with collaborations with GSK. An upcoming Investor R&D Day is set for December 4, 2023, to outline future strategies and progress.
Read more →IDYAIDEAYA Biosciences, Inc Reports Third Quarter 2023 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports Third Quarter 2023 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences Announces Plans for Investor R D Day and Participation in Jefferies London Healthcare Conference
IDEAYA Biosciences Announces Plans for Investor R D Day and Participation in Jefferies London Healthcare Conference
Read more →IDYAIDEAYA Announces Top Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ 11 Cutaneous Melanoma, and Synthetic Lethality Pipeline
IDEAYA Announces Top Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ 11 Cutaneous Melanoma, and Synthetic Lethality Pipeline
Read more →IDYAIDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ 11 Metastatic Cutaneous Melanoma
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ 11 Metastatic Cutaneous Melanoma
Read more →IDYAIDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R D Day
IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R D Day
Read more →IDYAIDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR , Her2 , BRCA1 2 mutant Breast Cancer
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR , Her2 , BRCA1 2 mutant Breast Cancer
Read more →IDYAIDEAYA Receives Fast Track Designation for Potential First in Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1 2 Mutations
IDEAYA Receives Fast Track Designation for Potential First in Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1 2 Mutations
Read more →IDYAIDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof of Concept for Potential First in Class PARG Inhibitor IDE161 in HRD Solid Tumors
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof of Concept for Potential First in Class PARG Inhibitor IDE161 in HRD Solid Tumors
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 IDE705
IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 IDE705
Read more →IDYAIDEAYA Announces First Patient In for Company Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in Neo Adjuvant Uveal Melanoma
IDEAYA Announces First Patient In for Company Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in Neo Adjuvant Uveal Melanoma
Read more →IDYAIDEAYA Biosciences, Inc Reports Second Quarter 2023 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports Second Quarter 2023 Financial Results and Provides Business Update
Read more →IDYAIDEAYA and Amgen Achieve First Patient In for Clinical Evaluation of IDE397 MAT2A and AMG 193 PRMT5 MTA Combination in MTAP Tumors
IDEAYA and Amgen Achieve First Patient In for Clinical Evaluation of IDE397 MAT2A and AMG 193 PRMT5 MTA Combination in MTAP Tumors
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event
Read more →IDYAIDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy
IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy
Read more →IDYAIDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP Deletion Solid Tumor Types
IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP Deletion Solid Tumor Types
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events
Read more →IDYAIDEAYA Announces IND Clearance Enabling Phase 1 2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP Deletion Solid Tumors
IDEAYA Announces IND Clearance Enabling Phase 1 2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP Deletion Solid Tumors
Read more →IDYAIDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma  Amended cl
IDEAYA Biosciences has extended its collaboration with Pfizer to support a Phase 2/3 registrational trial evaluating the combination therapy of darovasertib and crizotinib for first-line metastatic uveal melanoma (MUM). The trial is expected to initiate in Q2 2023, with progression-free survival as the primary endpoint for potential accelerated approval. IDEAYA is currently assessing the drug combination's efficacy in an ongoing Phase 2 trial, which has shown promising results. This collaboration underscores IDEAYA's commitment to developing targeted therapies in oncology.
Read more →IDYAIDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $351.2 million of cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. has reported its first quarter 2023 financial results, revealing a robust balance sheet with over $351 million in cash and equivalents. The company is set to initiate a Phase 2/3 registrational trial of its leading candidate, darovasertib, in combination with crizotinib for patients with HLA-A2 negative metastatic uveal melanoma. Additionally, IDEAYA is expanding its clinical trials for IDE397 and providing updates on multiple ongoing programs. The company anticipates significant clinical updates and milestones in the remainder of 2023.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event
Read more →IDYAIDEAYA Announces Pricing of Public Offering IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA ...
IDEAYA Biosciences, Inc. has announced the pricing of an underwritten public offering of common stock and pre-funded warrants, selling 7,439,201 shares at $18.50 each. They are also offering pre-funded warrants to purchase 2,020,270 shares at $18.4999. The total expected gross proceeds from the offering are approximately $175 million, which will be used to support the company's ongoing operations. The offering is expected to close around April 27, 2023, pending customary closing conditions.
Read more →IDYAIDEAYA Announces Proposed Public Offering of Common Stock
IDEAYA Announces Proposed Public Offering of Common Stock
Read more →IDYAIDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First Line Metastatic Uveal Melanoma
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First Line Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First in Class PARG Inhibitor Targeting HRD Solid Tumors
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First in Class PARG Inhibitor Targeting HRD Solid Tumors
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event
Read more →IDYAIDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First in Class Synthetic Lethality Programs IDE397 MAT2A , IDE161 PARG and Werner Helicase
IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First in Class Synthetic Lethality Programs IDE397 MAT2A , IDE161 PARG and Werner Helicase
Read more →IDYAIDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update • Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. reported its financial results for 2022, highlighting a robust balance sheet with approximately $373.1 million in cash and equivalents to support future operations. The company outlined plans for regulatory updates regarding the darovasertib/crizotinib combination therapy for metastatic uveal melanoma, with clinical efficacy data expected mid-2023. Additionally, IDEAYA is advancing its other programs, including IDE161 and IDE397, as part of its commitment to developing innovative oncology therapeutics.
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in March 2023
IDEAYA Biosciences to Participate in Investor Conferences in March 2023
Read more →IDYAIDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development ...
IDEAYA Biosciences, Inc. will participate in Citi's 2023 Virtual Oncology Leadership Summit, featuring a fireside chat with CEO Yujiro S. Hata. The event is scheduled for February 21, 2023, and will be accessible through a live audio webcast on IDEAYA's website. A replay of the event will also be available for 30 days post-event. This participation highlights IDEAYA's commitment to advancing its presence in the oncology sector.
Read more →IDYAIDEAYA Biosciences to Participate in Citis 2023 Virtual Oncology Leadership Summit
IDEAYA Biosciences to Participate in Citis 2023 Virtual Oncology Leadership Summit
Read more →IDYAIDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
Read more →IDYAIDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces IND Clearance by U S FDA enabling Phase 1 Initiation for First in Class PARG Development Candidate IDE161
IDEAYA Announces IND Clearance by U S FDA enabling Phase 1 Initiation for First in Class PARG Development Candidate IDE161
Read more →IDYAIDEAYA Biosciences to Present at the 41st Annual J P Morgan Healthcare Conference on Tuesday, January 10, 2023
IDEAYA Biosciences to Present at the 41st Annual J P Morgan Healthcare Conference on Tuesday, January 10, 2023
Read more →IDYAIDEAYA Biosciences Appoints Dr Karlene Cimprich, Ph D and Dr Kornelia Polyak, M D , Ph D to Scientific Advisory Board
IDEAYA Biosciences Appoints Dr Karlene Cimprich, Ph D and Dr Kornelia Polyak, M D , Ph D to Scientific Advisory Board
Read more →IDYAIDEAYA Biosciences Announces Submission of IND Application to the U S FDA for PARG Development Candidate IDE161
IDEAYA Biosciences Announces Submission of IND Application to the U S FDA for PARG Development Candidate IDE161
Read more →IDYAIDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma
IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R D Day Webcast on Monday, December 12, 2022
IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R D Day Webcast on Monday, December 12, 2022
Read more →IDYAIDEAYA Biosciences Appoints Darrin M Beaupre, M D , Ph D , as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
IDEAYA Biosciences Appoints Darrin M Beaupre, M D , Ph D , as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update • Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update -Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into 2026 -Reported Ph
Read more →IDYAIDEAYA Biosciences Announces Plans for Investor R D Day and Participation in Upcoming Investor Conferences
IDEAYA Biosciences Announces Plans for Investor R D Day and Participation in Upcoming Investor Conferences
Read more →IDYAIDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First Patient In for Multiple Combination Cohorts in MTAP Deletion Tumors
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First Patient In for Multiple Combination Cohorts in MTAP Deletion Tumors
Read more →IDYAIDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
Read more →IDYAIDEAYA Announces Pricing of Public Offering of Common Stock
IDEAYA Announces Pricing of Public Offering of Common Stock
Read more →IDYAIDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces First Patient In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in Neo Adjuvant Uveal Melanoma
IDEAYA Announces First Patient In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in Neo Adjuvant Uveal Melanoma
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in September 2022
IDEAYA Biosciences to Participate in Investor Conferences in September 2022
Read more →IDYAIDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First in Class Pol Theta Helicase Inhibitor Development Candidate
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First in Class Pol Theta Helicase Inhibitor Development Candidate
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update • Strong balance sheet of ~$324 million cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update -Strong balance sheet of ~$324 million cash, cash equivalents and marketable securities as of June 30, 2022 is anticipated to fund planned operations into 2025 -Initiated IDE397
Read more →IDYAIDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
Read more →IDYAIDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors Entered into Clinical Trial Collaboration and Supply Agreement with Amgen to clinica
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors South San Francisco, CA, July 27, 2022 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology compa
Read more →IDYAIDEAYA Announces Development Candidate Nomination of a Potential First in Class Pol Theta Helicase Inhibitor in Collaboration with GSK
IDEAYA Announces Development Candidate Nomination of a Potential First in Class Pol Theta Helicase Inhibitor in Collaboration with GSK
Read more →IDYAIDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
Read more →IDYAIDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update • Strong balance sheet of ~$346 million cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update -Strong balance sheet of ~$346 million cash, cash equivalents and marketable securities as of March 31, 2022 is anticipated to fund planned operations into 2025 -Targeting initia
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in May 2022
IDEAYA Biosciences to Participate in Investor Conferences in May 2022
Read more →IDYAIDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
Read more →IDYAIDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors - Dr. Mackey formerly served as Senior Vice President of Pfizer Worldwide Research and Development and as Director of Pfizer's La Jolla Labor
IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors - Dr. Mackey formerly served as Senior Vice President of Pfizer Worldwide Research and Development and as Director of Pfizer's La Jolla Laboratories South San Francisco, CA, April 6, 2022 IDEAYA Bios
Read more →IDYAIDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
Read more →IDYAIDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$368 million cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update South San Francisco, CA, March15, 2022 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of
Read more →IDYAIDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET Driven Tumors
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET Driven Tumors
Read more →IDYAIDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update
IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in March 2022
IDEAYA Biosciences to Participate in Investor Conferences in March 2022
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in February 2022
IDEAYA Biosciences to Participate in Investor Conferences in February 2022
Read more →IDYAIDEAYA Advances First in Class PARG Development Candidate, IDE161, into IND Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License
IDEAYA Advances First in Class PARG Development Candidate, IDE161, into IND Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License
Read more →IDYAIDEAYA Biosciences Announces Corporate and Portfolio Update for J P Morgan 40th Annual Healthcare Conference
IDEAYA Biosciences Announces Corporate and Portfolio Update for J P Morgan 40th Annual Healthcare Conference
Read more →IDYAIDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE TM Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform
IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE TM Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform
Read more →IDYAIDEAYA Biosciences Appoints Dr Frank McCormick as Chair of Scientific Advisory Board
IDEAYA Biosciences Appoints Dr Frank McCormick as Chair of Scientific Advisory Board
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in January 2022
IDEAYA Biosciences to Participate in Investor Conferences in January 2022
Read more →IDYAIDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre Treated Metastatic Uveal Melanoma
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre Treated Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in December 2021
IDEAYA Biosciences to Participate in Investor Conferences in December 2021
Read more →IDYAIDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$386 million cash, cash equivalents and marketable securities is anticipated to fund planned o
IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update South San Francisco, CA, November 15, 2021 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery a
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in November 2021
IDEAYA Biosciences to Participate in Investor Conferences in November 2021
Read more →IDYAIDEAYA Biosciences Appoints Michael White, Ph D , as Chief Scientific Officer
IDEAYA Biosciences Appoints Michael White, Ph D , as Chief Scientific Officer
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in September 2021
IDEAYA Biosciences to Participate in Investor Conferences in September 2021
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned
IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update South San Francisco, CA, August 10, 2021 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery an
Read more →IDYAIDEAYA Biosciences to Participate in Panel Discussion at 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021
IDEAYA Biosciences to Participate in Panel Discussion at 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021
Read more →IDYAIDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination
IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination
Read more →IDYAIDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
IDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
Read more →IDYAIDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update - Completed enrollment of initial dose escalation cohort of the Phase 1 clinical trial evaluating IDE397, a potential bes
IDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update South San Francisco, CA, May 10, 2021 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and de
Read more →IDYAIDEAYA Announces Dose Expansion in Phase 1 2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort
IDEAYA Announces Dose Expansion in Phase 1 2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort
Read more →IDYAIDEAYA to Participate in Upcoming May 2021 Investor Relations Event
IDEAYA to Participate in Upcoming May 2021 Investor Relations Event
Read more →IDYAIDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday April 20 2021
IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday April 20 2021
Read more →IDYAIDEAYA Reports Darovasertib IDE196 Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma
IDEAYA Reports Darovasertib IDE196 Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP Deletion Solid Tumors
IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP Deletion Solid Tumors
Read more →IDYAIDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib IDE196 Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma
IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib IDE196 Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces Dose Expansion in Phase 1 2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity
IDEAYA Announces Dose Expansion in Phase 1 2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity
Read more →IDYAIDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update - Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update South San Francisco, CA, March 23, 2021 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and
Read more →IDYAIDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG and Kinase Inhibitor IDE196
IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG and Kinase Inhibitor IDE196
Read more →IDYAIDEAYA to Participate in Upcoming March 2021 Investor Relations Events
IDEAYA to Participate in Upcoming March 2021 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day
IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day
Read more →IDYAIDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors - Dr. Susan L. Kelley was a former clinical development executive in oncology
IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors South San Francisco, CA, February 17, 2021 - IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine o
Read more →IDYAIDEAYA Announces IDE397 IND Clearance by U S FDA to Initiate Phase 1 and Appointment of Matthew Maurer M D as Vice President Head of Clinical Oncology and Medical Affairs
IDEAYA Announces IDE397 IND Clearance by U S FDA to Initiate Phase 1 and Appointment of Matthew Maurer M D as Vice President Head of Clinical Oncology and Medical Affairs
Read more →IDYAIDEAYA to Participate in Upcoming February 2021 Investor Relations Events
IDEAYA to Participate in Upcoming February 2021 Investor Relations Events
Read more →IDYASpelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry
Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry
Read more →IDYANASDAQ: IDYA Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences
IDEAYA Biosciences Improving Lives Through Transformative Precision Medicines JPM Healthcare Conference January 2021 Exhibit 99.1 NASDAQ: IDYA Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to
Read more →IDYAIDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U S FDA
IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U S FDA
Read more →IDYAIDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib a cMET Inhibitor
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib a cMET Inhibitor
Read more →IDYAIDEAYA to Participate in Upcoming January 2021 Investor Relations Events and Scientific Conferences
IDEAYA to Participate in Upcoming January 2021 Investor Relations Events and Scientific Conferences
Read more →IDYAIDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index
IDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update - IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND
IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update South San Francisco, CA, November 12, 2020 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t
Read more →IDYAIDEAYA to Participate in Upcoming November 2020 Investor Relations Events
IDEAYA to Participate in Upcoming November 2020 Investor Relations Events
Read more →IDYAIDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform
IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform
Read more →IDYAIDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations South San Francisco, CA
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations South San Francisco, CA, September 24, 2020 - IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncolo
Read more →IDYAIDEAYA to Participate in Upcoming September 2020 Investor Relations Events
IDEAYA to Participate in Upcoming September 2020 Investor Relations Events
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update - Established strategic partnership with GlaxoSmithKline on Synthetic Lethality programs MAT2A, Pol Theta and Werner Hel
IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update South San Francisco, CA, August 12, 2020 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of ta
Read more →IDYAIDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment - Closing of Glaxo Group Equity Investment of $20 Million in IDEAYA at $15.00 per share - Co
IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment South San Francisco, CA, August 4, 2020 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the disco
Read more →IDYAIDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ 11 Basket Trial
IDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ 11 Basket Trial
Read more →IDYAIDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12 2020
IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12 2020
Read more →IDYAIDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib a MEK Inhibitor
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib a MEK Inhibitor
Read more →IDYAIDEAYA Appoints Garret Hampton Ph D to the Board of Directors an Industry Leader in Precision Medicine Oncology and Diagnostics
IDEAYA Appoints Garret Hampton Ph D to the Board of Directors an Industry Leader in Precision Medicine Oncology and Diagnostics
Read more →IDYAExibhit 99.1 IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics - Dr. Garret Hampton serves as President, Clinical Sequencing and Oncology
IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics South San Francisco, CA, June 30, 2020 - IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the d
Read more →IDYAIDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology Partnership covers three IDEAYA Synthetic Lethality programs - MAT2A, Pol Theta and Werner Helicase, an
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology South San Francisco, CA, and London, United Kingdom, June 16, 2020 - IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic pa
Read more →IDYAIDEAYA Biosciences Selected to Join Russell 3000® Index IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted...
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 8, 2020 , ranking them by total market capit
Read more →IDYAIDEAYA Biosciences Selected to Join Russell 3000 R Index
IDEAYA Biosciences Selected to Join Russell 3000 R Index
Read more →IDYAIDEAYA Announces Nomination of Development Candidate IDE397 for MAT2A Synthetic Lethality Program Targeting MTAP Deletion Patient Population
IDEAYA Announces Nomination of Development Candidate IDE397 for MAT2A Synthetic Lethality Program Targeting MTAP Deletion Patient Population
Read more →IDYAIDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday June 2 2020
IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday June 2 2020
Read more →IDYAIDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ 11 Tumors and Preclinical MAT2A Synthetic Lethality Program
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ 11 Tumors and Preclinical MAT2A Synthetic Lethality Program
Read more →IDYAIDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update South San Francisco, CA
IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update South San Francisco, CA, May 12, 2020 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of target
Read more →IDYAIDEAYA Biosciences Announces Addition of Julie Patel as Vice President Human Resources Enhancing its Leadership Team
IDEAYA Biosciences Announces Addition of Julie Patel as Vice President Human Resources Enhancing its Leadership Team
Read more →IDYAIDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA, March 24, 2020 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of tar
Read more →IDYAIDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations
IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations
Read more →IDYAIDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update
IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update
Read more →IDYAIDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities South San Francisco, CA
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities South San Francisco, CA, March 11, 2020 - IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused
Read more →IDYAIDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020
IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020
Read more →IDYACOMPANY LOGO]" Safe Harbor Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performan
IDEAYA Biosciences Corporate Presentation JP Morgan Conference January 2020 Exhibit 99.1 "[COMPANY LOGO]" Safe Harbor Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events o
Read more →IDYAIDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted...
Under the agreement, IDEAYA will collaborate with and support research at Boston Children's Hospital in the laboratory of Dr. Joyce Bischoff , Ph.D., Research Associate, Department of Surgery and Professor, Harvard Medical School , who is Principal Investigator of the research st
Read more →IDYAIDEAYA Biosciences and Boston Childrens Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome a Rare Disease Associated with Genetic Mutation of GNAQ
IDEAYA Biosciences and Boston Childrens Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome a Rare Disease Associated with Genetic Mutation of GNAQ
Read more →IDYAIDEAYA Biosciences to Present at the 38th Annual J P Morgan Healthcare Conference on Wednesday January 15 2020
IDEAYA Biosciences to Present at the 38th Annual J P Morgan Healthcare Conference on Wednesday January 15 2020
Read more →IDYAIDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors
IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors
Read more →IDYAExibhit 99.1 IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors South San Francisco, CA
IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors South San Francisco, CA, December 18, 2019 - IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat canc
Read more →IDYAIDE196 Program Updates Targeting Initiation of Potentially Registration Enabling Phase 2 Single Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020
IDE196 Program Updates Targeting Initiation of Potentially Registration Enabling Phase 2 Single Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020
Read more →IDYAPhase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress - Robust enrollment, with 27 total patients enrolled in the Phase 1 dose escalation portion, including 12 patients in MUM DLT c
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress South San Francisco, CA, November 20, 2019 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted
Read more →IDYAPhase 1 2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress
Phase 1 2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update - Single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy
IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA, November 13, 2019 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t
Read more →IDYAIDEAYA Biosciences Announces Leadership Updates in Research Organization
IDEAYA Biosciences Announces Leadership Updates in Research Organization
Read more →IDYAIDEAYA Biosciences Reports End of Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single Arm Trial Design for Potential Phase 2 Registration Enabling Study in Metastatic Uveal Melanoma
IDEAYA Biosciences Reports End of Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single Arm Trial Design for Potential Phase 2 Registration Enabling Study in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Biosciences to Present at Upcoming Investor Conferences
IDEAYA Biosciences to Present at Upcoming Investor Conferences
Read more →IDYAIDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor Agnostic GNAQ 11 Basket Trial
IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor Agnostic GNAQ 11 Basket Trial
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA
IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA, August 12, 2019 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of tar
Read more →IDYAIDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1 2 Tissue Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1 2 Tissue Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
Read more →IDYAIDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone J D as Chief Financial Officer Andres Ruiz Briseno C P A as Vice President Finance and Mick OQuigley M B A as Vice President Development Operations
IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone J D as Chief Financial Officer Andres Ruiz Briseno C P A as Vice President Finance and Mick OQuigley M B A as Vice President Development Operations
Read more →IDYAIDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares South San Francisco, CA
IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares South San Francisco, CA, May 28, 2019 IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its initial public offering of 5,7
Read more →IDYAIDEAYA Announces Pricing of Initial Public Offering
IDEAYA Announces Pricing of Initial Public Offering
Read more →IDYAIDEAYA Receives Authorization to Proceed with Phase 1 2 Tissue Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ 11 Mutations and PKC Fusions
IDEAYA Receives Authorization to Proceed with Phase 1 2 Tissue Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ 11 Mutations and PKC Fusions
Read more →IDYAUpdated Phase 1 Clinical Trial Monotherapy Data for IDE196 in Metastatic Uveal Melanoma to be Presented at AACR Conference
Updated Phase 1 Clinical Trial Monotherapy Data for IDE196 in Metastatic Uveal Melanoma to be Presented at AACR Conference
Read more →IDYAIDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick Ph D FRS and William Sellers M D to Scientific Advisory Board
IDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick Ph D FRS and William Sellers M D to Scientific Advisory Board
Read more →IDYAIDEAYA Biosciences to Present at the 37th Annual J P Morgan Healthcare Conference on Tuesday January 8 2019
IDEAYA Biosciences to Present at the 37th Annual J P Morgan Healthcare Conference on Tuesday January 8 2019
Read more →IDYAIDEAYA Biosciences Inc appoints Bao Truong as Vice President Head of Regulatory Affairs
IDEAYA Biosciences Inc appoints Bao Truong as Vice President Head of Regulatory Affairs
Read more →IDYAIDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations IDEAYA Biosciences, Inc., has entered into an exclusive license agreement with Novartis to develop and commercialize Novartis' LXS196, a Phase 1...
SOUTH SAN FRANCISCO, Calif. , Oct. 23, 2018 /PRNewswire/ -- IDEAYA Biosciences, Inc., has entered into an exclusive license agreement with Novartis to develop and commercialize Novartis' LXS196, a Phase 1 protein kinase C (PKC) inhibitor for the treatment of cancers with GNAQ and
Read more →IDYAIDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations
IDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations
Read more →IDYAIDEAYA Biosciences to Present at the 2018 Jefferies Global Healthcare Conference
IDEAYA Biosciences to Present at the 2018 Jefferies Global Healthcare Conference
Read more →IDYAIDEAYA Biosciences Appoints Paul Stone J D as Senior Vice President and General Counsel Head of Operations and Mark Lackner Ph D as Vice President Head of Biomarkers and Synthetic Lethal Biology
IDEAYA Biosciences Appoints Paul Stone J D as Senior Vice President and General Counsel Head of Operations and Mark Lackner Ph D as Vice President Head of Biomarkers and Synthetic Lethal Biology
Read more →IDYAIDEAYA Biosciences Appoints Julie Hambleton M D as Senior Vice President and Chief Medical Officer Head of Development
IDEAYA Biosciences Appoints Julie Hambleton M D as Senior Vice President and Chief Medical Officer Head of Development
Read more →IDYAIDEAYA Biosciences Raises 94 Million Crossover Series B Financing
IDEAYA Biosciences Raises 94 Million Crossover Series B Financing
Read more →IDYAIDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG
IDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG
Read more →IDYAIDEAYA Biosciences Appoints Julie Hambleton, M.D., as Senior Vice President and Chief Medical Officer, Head of Development IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and...
SOUTH SAN FRANCISCO, Calif. , March 13, 2018 /PRNewswire/ -- IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, announced today the appointment of Julie Hamble
Read more →IDYAIDEAYA Biosciences to Present at the 36th Annual J P Morgan Healthcare Conference
IDEAYA Biosciences to Present at the 36th Annual J P Morgan Healthcare Conference
Read more →IDYAIDEAYA Biosciences to Participate in Emerging Innovators Panel at Citis 12th Annual Biotech Conference
IDEAYA Biosciences to Participate in Emerging Innovators Panel at Citis 12th Annual Biotech Conference
Read more →IDYAFierceBiotech names IDEAYA Biosciences as one of its Fierce 15 Biotech Companies of 2016 IDEAYA Biosciences, an oncology-focused biotechnology company committed to the discovery of breakthrough small molecule synthetic lethality and...
SAN FRANCISCO and SAN DIEGO , Sept. 19, 2016 /PRNewswire/ -- IDEAYA Biosciences, an oncology-focused biotechnology company committed to the discovery of breakthrough small molecule synthetic lethality and immune-oncology therapies, today announced that it has been named by Fierce
Read more →IDYAFierceBiotech names IDEAYA Biosciences as one of its Fierce 15 Biotech Companies of 2016
FierceBiotech names IDEAYA Biosciences as one of its Fierce 15 Biotech Companies of 2016
Read more →IDYAIDEAYA Biosciences Raises 46 Million Series A and Recruits Leadership and Advisory Board
IDEAYA Biosciences Raises 46 Million Series A and Recruits Leadership and Advisory Board
Read more →Competitive Position
How IDYA ranks across every disease it competes inCompetitive Position is a premium feature
See how IDYA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial